NCT04906590View on ClinicalTrials.gov

PPMI Tau PET Imaging

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 30, 2021

Primary Completion Date

January 30, 2023

Study Completion Date

February 1, 2023

Conditions
Parkinson Disease
Interventions
DRUG

[18F] PI-2620

Evaluation of the radiopharmaceutical imaging agent PI-2620 in detecting TAU brain burden.

Trial Locations (1)

06510

Institute for Neurodegenerative Disorders, New Haven

All Listed Sponsors
collaborator

Institute for Neurodegenerative Disorders

OTHER

lead

Michael J. Fox Foundation for Parkinson's Research

OTHER

NCT04906590 - PPMI Tau PET Imaging | Biotech Hunter | Biotech Hunter